Close Menu

NEW YORK (GenomeWeb) – Stanford University's Park Institute for Cancer Immunotherapy and Epinomics announced they have agreed to collaborate on improving cancer immunotherapies by utilizing biomarkers and epigenomics technology.

Immunotherapy has been shown to be a promising approach for the effective treatment of cancer, including achieving long term remission in patients who have not responded to existing therapies, Epinomics Cofounder Paul Giresi said in a statement. However, he noted, there is no gold standard for the application or monitoring for this type of therapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.